Eli Lilly and Company (LLY)vsSIGA Technologies Inc (SIGA)
LLY
Eli Lilly and Company
$1,372.99
+6.63%
HEALTHCARE · Cap: $1.12T
SIGA
SIGA Technologies Inc
$3.31
+3.44%
HEALTHCARE · Cap: $226.69M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 148367% more annual revenue ($79.67B vs $53.66M). LLY leads profitability with a 33.5% profit margin vs -5.2%. LLY appears more attractively valued with a PEG of 1.14. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
SIGA
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+55.6%
Fair Value
$14.96
Current Price
$3.31
$11.65 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Reasonable price relative to book value
Strong operational efficiency at 33.9%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 36.1x book value
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Revenue declined 49.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : SIGA
The strongest argument for SIGA centers on Price/Book, Operating Margin, Debt/Equity.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 42.2x leaves little room for execution misses. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : SIGA
The primary concerns for SIGA are Market Cap, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
LLY profiles as a growth stock while SIGA is a turnaround play — different risk/reward profiles.
SIGA carries more volatility with a beta of 0.96 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 35/100), backed by strong 33.5% margins and 47.7% revenue growth. SIGA offers better value entry with a 55.6% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →SIGA Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health safety and infectious disease markets in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?